
Purpose of review National policy recommendations on prostate cancer early detection using prostate-specific antigen (PSA) have focused on determining whether the evidence in favor of screening is sufficiently strong to warrant population-based implementation. We review the literature using the alternative framework of decision-analytic evaluation of screening policy. Recent findings Randomized trial data are very clear: while PSA screening does reduce mortality, it remains open to question whether this benefit outweighs the well known harms resulting from overdiagnosis and overtreatment. But recent research on use of markers and MRI to reduce overdiagnosis and active surveillance to reduce overtreatment have transformed our ability to reduce the harms of prostate cancer. Almost all high-income countries have PSA policies based on shared decision-making. This sort of disorganized screening has led to the worse possible outcomes of high harm, low benefit and gross inequity. A modeling study has shown implementation of population-based screening would reduce both PSA testing and prostate cancer overdiagnosis. Summary High-income countries need to make the hard choice between a population-based screening program carefully designed to reduce the harms of PSA – that is, organized screening – or restrict PSA screening altogether.
Purpose of review Since its inception in urologic procedures, robotic platforms have changed dramatically. These include developments in surgeon control, sensory feedback, and haptics. The purpose of this review is to summarize current findings and research in these domains. Recent findings Most robots in urology are level I, which is complete surgeon control with no ability to perform tasks without direct manipulation by the operator. Visual sensation is the main feedback in robotic assisted surgery, which can be enhanced with augmented reality and auditory cues like auto-stop. Haptics attempt to restore tissue properties like touch, pressure, and tension lost in robotic surgery. A recent example of this is force feedback when grasping tissues. Summary Surgeon control in robotics does not exist beyond level III, whereby the robot can execute independent surgical tasks with surgeon input. Sensation beyond visual and auditory cues remains an area for improvement. Multiple studies show haptic technology improves surgeon performance.
Purpose of review Prostate cancer screening is undergoing a major transition from opportunistic prostate-specific antigen (PSA) testing to organized, risk-stratified screening programs. This review summarizes current evidence on established screening modalities, emerging biomarkers, and evolving screening pathways designed to improve the detection of clinically significant prostate cancer (csPCa) whilst reducing overdiagnosis and unnecessary interventions. Recent findings Long-term follow-up from the European Randomized Study of Screening for Prostate Cancer confirms a reduction in prostate cancer-specific mortality associated with screening. Multiparametric magnetic resonance imaging (mpMRI) has become a central component of contemporary diagnostic pathways, improving the detection of csPCa and reducing unnecessary biopsies. Novel blood- and urine-based biomarkers, including PHI, 4Kscore, Stockholm3, SelectMDx, PCA3, MiPS, and ExoDx, have demonstrated improved risk stratification compared with PSA alone and may further refine biopsy selection. Organized screening programs increasingly integrate PSA, MRI, and biomarker-based assessment. Summary Current evidence supports risk-adapted screening approaches combining PSA, mpMRI, and validated biomarkers to maximize the detection of clinically significant disease while minimizing screening-related harms. Future screening programs are likely to incorporate artificial intelligence and integrated risk-prediction models, enabling more personalized, accurate, and cost-effective prostate cancer early detection.
Purpose of review To evaluate the impact of laser-based and water-based therapies for benign prostatic hyperplasia on quality of life (QoL) and sexual function, with emphasis on patient-reported outcomes and functional preservation. Recent findings Both laser and water-based therapies provide meaningful improvements in urinary symptoms and QoL. Laser enucleation techniques, particularly HoLEP and thulium laser, have the most established evidence for durable symptom relief but are commonly associated with ejaculatory dysfunction after standard procedures. Available evidence suggests that some water-based therapies may provide greater preservation of ejaculatory function while achieving meaningful symptom improvement, although direct comparative evidence is limited. Aquablation has randomized comparative and longer-term evidence, while Rezūm demonstrates sustained patient-reported benefits with preservation of sexual function but has a distinct mechanism and evidence base. Early studies of 450-nm blue laser therapy report favorable QoL and sexual outcomes; however, evidence is limited to small studies with short follow-up. Summary Laser and water-based therapies provide meaningful improvements in QoL, but their evidence base, durability, and functional outcomes differ. Treatment selection should be individualized according to symptom burden, prostate characteristics, durability of evidence, functional priorities, and patient preferences.
Purpose of review To synthesize contemporary, high-quality evidence on optimizing microdissection testicular sperm extraction (micro-TESE) outcomes for men with nonobstructive azoospermia (NOA). This review transitions the focus from plateaued baseline retrieval rates to a precision-based, surgeon-centric clinical pathway encompassing comprehensive preoperative, intraoperative, and laboratory domains. Recent findings Preoperative risk stratification is evolving beyond isolated clinical markers. Emerging multivariable nomograms and investigational liquid biopsies, such as seminal extracellular vesicle RNAs, offer refined predictive capabilities. Current evidence strongly supports selective varicocele repair prior to micro-TESE to significantly improve sperm retrieval and clinical pregnancy odds in specific cohorts. Conversely, hormonal optimization demands a targeted, phenotype-directed approach, emphasizing aromatase inhibitors for patients with a low testosterone-to-estradiol ratio, while the routine empirical use of clomiphene citrate remains contentious. Intraoperatively, advanced mapping modalities, including contrast-enhanced ultrasound and robotic-assisted platforms, provide high-resolution navigation. However, the systematic identification of dilated seminiferous tubules under high optical magnification, coupled with real-time embryological feedback, remains the definitive cornerstone of surgical success. Furthermore, the adjunctive use of artificial intelligence in embryological processing demonstrates significant potential in accelerating rare sperm detection. Summary Surpassing the current ceiling of micro-TESE success requires a highly individualized, multidisciplinary strategy. This encompasses rigorous genetic and endocrine profiling, phenotype-specific preoperative optimization, and meticulous, tissue-sparing microsurgical techniques. As noninvasive biomarkers and artificial intelligence transition into clinical maturity, their integration will further refine patient selection and intraoperative decision-making, ultimately elevating the standard of care for this severe cohort of male infertility.